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This article describes a 45 year old woman with a 13cm right ovarian leiomyoma (OL) coexisting with multiple uterine 
fibroids. Ovarian leiomyoma is rare, there are only few reports from Africa but it is likely that the incidence from Africa is 
under‑reported. There was no associated abdominal pain in spite of the size of the mass and multiple adhesions from a 
previous myomectomy done 12 years prior to this presentation. We discuss the relevance of the size of an ovarian mass 
to clinical management and the other factors guiding the choice of the appropriate management options in patients with 
ovarian masses, such as the age of the patient, the clinical symptoms, the risk of malignancy, the desire for future fertility 
and the proximity to menopause. The clinical (including ultrasonographic features), histopathologic, immunohistochemical 
and molecular features of the disease are also discussed.
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Introduction
Ovarian leiomyoma (OL) is a rare benign tumor accounting 
for 0.5%–1% of all benign ovarian tumors.[1] Most primary 
adnexal leiomyomas occur in women age 20–65 years with 
approximately 15% of cases occurring in postmenopausal 
women.[2]
We present a 45-year-old premenopausal woman with 
a medium-sized OL coexisting with multiple uterine 
leiomyomas. There are only few reports of OL from Africa 
such as the one from Nigeria by Okoye IJ, Okezie OO in 
2000 (http://dx.doi.org/10.4314/wajr.v7i1.34175), and from 
Tanzania by Lema et al. in 2013. The ovarian mass in the index 
patient was missed during ultrasonography and we hope that 
this report would create awareness about this rare disease 
among sonographers, primary care physicians, gynecologists, 
and histopathologists.
We present clinicopathologic findings in this patient, review 
the existing literature, and discuss the appropriate diagnostic 
work-up with a focus on the relevance of the size of anovarian 
mass to clinical management, and other considerations 
guiding the choice of appropriate management.
Case Report
A 45-year-old Para 1 woman presented at a private medical 
center in Lagos, Nigeria, in May 2016 with heavy menstrual 
bleeding and an abdominal mass. There was no abdominal 
pain or discomfort. She had a myomectomy in 2004 on 
account of symptomatic uterine fibroids. She also had a 
caesarean delivery in 2005, for her only confinement. She 
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was desirous of further pregnancies and had been trying to 
conceive.
On examination, she was found to be overweight (body 
mass index of 28.80 kg/m2) and mildly pale (hemoglobin 
of 11.4 g/dL). The abdomen was distended and the uterus was 
28-week sized with multiple fibroids palpable par abdomen. 
Transvaginal ultrasound scan confirmed a large uterus with 
multiple fibroids. There was no documentation of a mass in 
the ovary in the patient’s ultrasound scan report.
A diagnosis of symptomatic uterine fibroids was made; 
myomectomy was done and the uterus conserved in 
consideration of her desire for future conception. A right 
ovarian mass was found at surgery, along with multiple pelvic 
adhesions, and a 26-week-sized uterus with multiple fibroids 
of different sizes at subserosal, intramural, and submucosal 
locations. The right ovary contained a solid tumor measuring 
13 cm × 10 cm × 6 cm. The right ovarian mass was excised. 
The left ovary was normal in size and appearance.
Grossly, there were 30 greyish-white firm nodules 
altogether weighing 800 g and ranging in size between 
1 × 0.5 × 0.5 cm and 7 × 6 × 3 cm. There was a 700-g 
right ovarian mass with an intact capsule which measured 
13.0 × 9.0 × 5.0 cm. Cut sections through all the nodules 
and the right ovarian mass showed a greyish-white whorled 
appearance [Figure 1]. Microscopic examination of the ovarian 
mass showed a well-circumscribed benign mesenchymal 
neoplasm surrounded by a rim of normal ovarian tissue 
stroma [Figure 2]. The tumor was composed of whorls and 
interlacing fascicles of uniform spindle-shaped cells with 
blunt-ended cigar-shaped nuclei. There was no evidence of 
nuclear atypia or pleomorphism. Mitosis was not observed. 
Immunohistochemical staining showed strong and diffuse 
positive staining for smooth muscle actin and desmin. The 
tumor was completely negative for Inhibin. Ki-67 was less 
than 1%. These histologic and immunohistochemical features 
are consistent with those of an OL.
Discussion
The first case of OL was described by Sangalli et al. in 1862. 
Since then, less than 100 cases of this rare tumor have been 
reported.[3,4] The majority of the cases in scientific literature 
exist as independent reports, along with a few case series 
including the ones by Fallahzadeh et al.[5] of 5 cases in 1972, 
Doss et al.[6] of 19 cases in 1999, and Koo et al.[7] of 9 cases 
in 2011.
OL is rare, with only a few reports from Africa. This disease 
may be under-reported among Africans, more likely due to a 
failure to publish cases than to difficulties with recognition of 
this entity with clearly defined histopathologic features. The 
counterpart of this tumor in the uterus is diagnosed often 
by an average Nigerian pathologist. Uterine leiomyoma is 
the most common benign tumor of the female genital tract 
seen in Nigeria.[8] Uterine leiomyoma is known to be more 
common in blacks than in whites, and the lifetime risk of 
fibroids in a woman over the age of 45 years is more than 
60%.[9] Some cases of OL among Africans may not be fit for 
publication because a definitive diagnosis was not obtained 
due to lack of access to immunohistochemistry and failure 
to exclude the differential diagnoses.
Figure 1: (a) The gross appearance of the ovarian mass with cut‑surfaces 
showing a  greyish‑white whorled appearance.  (b) Ovarian  leiomyoma 
(bottom  right)  surrounded  by  ovarian  stroma  (top  left)  (H&E  x40). 
(C) Histologic section showing sheets of  uniform spindle‑shaped cells with 
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OL appears to be most commonly reported from Eurasia, with 
five reports from India (Gunasekaran et al., 2015;[10] Sasikala 
et al., 2014; Agrawal et al., 2013,[11] Jena et al., 2013; and 
Ramalakshmi et al., 2009); four from Turkey (Kelekci et al., 
2015; Taskin et al., 2014; Guzel et al., 2014; and Cavkaytar 
et al., 2010); and two each from South Korea (Koo et al., 2011 
and Kim et al., 2000), Japan (Ichigo et al., 2015 and Kozawa 
et al., 2013), and Iran (Rajabi et al. 2014 and Safaei et al., 
2011). Koo et al. found nine cases in a period of 17 years 
in South Korea.[7] There is also a paucity of reports from 
Europe and North America which could be as a result of a 
lack of interest of researchers and/or journals in this rare but 
well-described entity.
OLs can be primary, secondary, or parasitic in origin. Primary 
OLs are defined as lesions that originate from ovarian tissues, 
including the intraovarian blood vessels, smooth muscle 
fibers, or similar tissues within the ovarian stroma and tunica 
albuginea.[7] Secondary involvement of the ovaries can occur 
from intravenous leiomyomatosis or from leiomyomatosis 
peritonealis disseminata.[12] Parasitic OLs are extraovarian 
in origin, often originating from a pedunculated uterine 
leiomyoma that becomes pinched off and secondarily 
attached to the ovary.[7,11,13] The incidence of primary ovarian 
leiomyomas is particularly low.[7]
OL may originate from smooth muscle fibers which may be 
found in the ovarian stroma, in the ovarian hilar blood vessels, 
smooth muscles, in mature cystic teratomas, and in the walls 
of mucinous cystic tumors.[1] Other possible origins for an 
OL include cells in the ovarian ligament, multipotential cells 
in the ovarian stroma, undifferentiated germ cells, cortical 
smooth muscle metaplasia, or smooth muscle metaplasia of 
endometriotic stroma.[1]
OLs are usually unilateral, with no predilection for the left or 
the right side.[11] Bilateral cases appear to be more common in 
patients younger than 35 years.[1,11] The first case of bilateral 
OL was reported in a 21-year-old by Kandalaft et al. in 1992. 
Several previous reports state that no case of bilateral OL had 
ever been seen in a patient older than 35 years (Usta et al., 
2006; Wei et al., 2008; Tomas et al., 2009; van Esch et al., 2011; 
Lema et al., 2013; Zhao et al., 2014). In 2011 however, a case 
of bilateral disease was reported from the Netherlands in a 
37-year-old woman.[2] The index patient had a right ovarian 
mass, while the left ovary was completely free of masses.
Along with the ovarian mass, the index patient had multiple 
fibroid nodules in the uterus. Doss reported that 78% of 
the 19 cases described in their series had OLs coexisting 
with uterine leiomyomas.[6] The hormone estrogen has 
been implicated in the growth and development of both 
ovarian and uterine leiomyomas.[4,11] Hormonal dependency 
of these tumors is evidenced by the increased incidence in 
the reproductive age with reduced incidence before puberty, 
after menopause, and in males; the increase in size during 
pregnancy; and their postpartum regression.[12]
The first case of OL in a patient who was yet to attain 
menarche was reported in 2014 by Blue et al. Far more cases 
have been described in postmenopausal women, with up to 
15% of cases occurring in postmenopausal women.[2] Three of 
the four cases in postmenopausal women that we reviewed 
for this article occurred in women in their late 40s to early 50s 
who were likely in their early menopause years.[14-16] Two of 
the nine patients studied by Koo et al. were postmenopausal 
women, in their 50s, and also likely to have been in the early 
menopause years. The fourth case occurred in a 76-year-old 
woman.[17] We suggest the possibility that this fourth patient 
may have been on hormone replacement therapy.
Up to 70% of patients with uterine leiomyomas carry somatic 
mutations in the mediator complex subunit 12 (MED12) exon 
2 which have been implicated in tumorigenesis.[18] Since OLs 
also originate from smooth muscle cells, it is hypothesized 
that similar mutations could be present in OLs. Kämpjärvi 
et al. studied 42 cases of extrauterine leiomyomas and found 
that none showed somatic MED12 mutations.[18]
Rarely, multiple OLs may occur in patients with Gorlin 
syndrome (GS).[19,20] Ovarian fibroma, a far more common 
manifestation of GS than OL, is found in 12%–25% of 
patients with GS, and it is a minor criterion for the 
diagnosis of GS.[19] GS, otherwise known as nevoid basal cell 
carcinoma syndrome, is an autosomal dominant disorder 
resulting from a mutation in PTCH1 gene on chromosome 
9q22.[19] It is associated with various congenital anomalies 
and development of tumors including basal cell carcinomas 
and keratocystic odontogenic tumors.[19]
The index patient presented with menorrhagia, likely due 
to the associated uterine fibroids. There was no history of 
associated abdominal pain or discomfort at presentation. 
The ovarian mass was discovered incidentally at surgery, 
and she had no symptoms suggestive of an OL. OL is usually 
asymptomatic, and it is often discovered as an incidental 
finding during routine physical examination, at surgery or at 
autopsy.[1] In symptomatic cases, clinical features that have 
been described include abdominal pain, a palpable mass, 
hydronephrosis, elevated CA-125 levels, hydrothorax, and 
ascites.[1,2]
Abdominal pain is the most common presenting symptom 
among patients with ovarian masses.[21] Acute or chronic 
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pain accounts for more than 10% of referrals to gynecologists 
and 40% of gynecologic diagnostic laparoscopies.[22] Ovarian 
masses cause abdominal pain due to their mass effect 
on adjacent tissue, by inciting the formation of fibrous 
adhesions, especially after surgery, and from the presence of 
endometrial tissue (endometriosis).[23] The fact that ovarian 
masses can cause pain directly from their mass effect on 
adjacent tissue suggests that the larger an ovarian mass is, 
the more likely it is to be associated with clinical symptoms. 
In the case reported by van Esch et al., the complaints of 
abdominal discomfort disappeared shortly after resection 
of the ovarian masses.[2]
After extensive literature search, we found only one case 
of OL larger than 10 cm in diameter (19 cm) that was not 
associated with lower abdominal pain and occurring in a 
76-year-old woman. Daoust et al. demonstrated a linear 
decrease with age of scores for visceral pain among persons 
in the 18–44, 45–64, 65–74, and >75 year age groups, but 
the differences identified were not found to be statistically 
significant.[24]
All the other cases documented in scientific literature 
with diameter greater than 10 cm were associated with 
lower abdominal pain or discomfort, often chronic and 
lasting for periods ranging from 1 month to 2 years before 
presentation (Sasikala et al., 2014; Rajabi et al., 2014; Agrawal 
et al., 2013; Kozawa et al., 2013; Jena et al., 2013; Safaei 
et al., 2011;[16] Cavkaytar et al., 2010; Tomas et al., 2009; 
Ramalashkmi et al., 2009). Pain was chronic in most cases, 
but rarely it could be intermittent or acute if it arises from 
an endometriotic cyst or is associated with complications.[1,15]
In spite of the size of 13-cm diameter ovarian mass in the 
index patient, and the multiple adhesions from a previous 
myomectomy done 12 years earlier, there was no associated 
lower abdominal pain or discomfort, and there was no 
tenderness elicited on physical examination.
A wide range of tumor sizes have been reported for OL.[4] 
Several articles report that OLs are usually small, they 
measure only a few millimeters in diameter, and they are 
often no larger than 3 cm diameter.[1,2,11] However, there have 
been several recent reports of masses with diameter greater 
than 10 cm (as listed above). The largest mass documented 
in literature measures 25 cm in widest diameter.[11]
A small OL may also present with symptoms, especially if it 
becomes associated with complications. Guzel et al. described 
a patient with a 6-cm diameter OL who presented on account 
of acute pain due to torsion.[25] Other causes of acute pain 
from an ovarian mass include rupture of an ovarian cyst, 
hemorrhage into a cyst, acute pelvic infections, malignancy, 
and non-gynecological causes.[26] Taskin et al. described a 4-cm 
diameter OL with lower abdominal pain, in the absence of 
complications, the absence of fibrous adhesions, and without 
being associated with uterine leiomyoma.[13]
The main goal in the evaluation of an adnexal mass is 
to differentiate between benign conditions and more 
serious diseases such as ovarian cancer.[27] Ovarian cancer 
is the most frequent cause of death from gynecological 
malignancies in the Western world.[27,28] The preferred 
imaging modality for the initial evaluation of an adnexal 
mass is ultrasonography.[26,29,30] This is because it is the 
least invasive and the most cost-effective method that is 
available.[29] The relative echogenicity of leiomyomas depends 
on the ratio of fibrous tissue to smooth muscle, the extent of 
degeneration, and the presence of dystrophic calcification.[29] 
A computerized tomography (CT) scan can be useful even 
though leiomyomas are indistinguishable from healthy 
myometrium unless they calcify or become necrotic.[29] 
Magnetic resonance imaging (MRI) can define the anatomy 
of the uterus and ovaries, but the availability of this method 
and its high cost are serious limitations.[29]
Ultrasound findings in OL are similar to those for uterine 
leiomyoma.[22] Two-dimensional ultrasound is readily 
available in most cosmopolitan cities across Nigeria. New 
advances, such as three-dimensional (3D) sonography, 3D 
vascular assessment, and contrast imaging, show promise 
for augmenting diagnostic accuracy.[22]
On MRI, OLs show intermediate signal intensity on 
T1-weighted images and low signal intensity on T2-weighted 
images.[12] Ovarian fibroma is the most important entity to 
consider in the differential diagnosis.[12] The early contrast 
enhancement of leiomyomas may aid in their differentiation 
from other fibrous ovarian tumors such as fibromas or 
fibrothecomas, which usually demonstrate delayed weak 
enhancement.[12] There are rare reports of extensive cystic 
degeneration in ovarian vascular leiomyomas, a feature 
that causes them to closely resemble cystic tumors such as 
cystadenomas.[12]
During initial evaluation with ultrasonography, the size 
of the adnexal mass is determined. Aside of suggesting 
the likelihood of finding associated clinical symptoms or 
complications in an ovarian mass, the size of an ovarian mass 
plays a crucial role in suggesting the risk of malignancy and in 
predicting the likelihood of success of laparoscopic surgery.[26]
In 2009, Givens et al., in a consensus paper released on 
behalf of the American Academy of Family Physicians (AAFP), 
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recommended that prepubescent girls and postmenopausal 
women with an adnexal mass should be referred to a 
gynecologist or gynecologic oncologist for further treatment, 
and that all women, regardless of menopausal status, should 
be referred if they have evidence of metastatic disease, 
ascites, a complex mass, an adnexal mass greater than 10 cm, 
or any mass that persists longer than 12 weeks.[27] Prior to 
the paper by Givens et al., the cut-off size of uterine adnexal 
tumors for surgical intervention in the early detection of 
cancer had not yet been well-determined.[28] In 2016, a new 
consensus paper showed that the AAFP had reviewed the 
cut-off size for referral for surgical intervention to 6 cm.[30]
Al-Shukri studied 57 women with adnexal masses who had 
surgical intervention on account of acute symptoms and found 
that the size of the mass seemed to contribute significantly 
toward the success of laparoscopic surgery.[26] Conversion of 
surgical approach from laparoscopy to laparotomy became 
necessary in >50% of the patients studied due to the size of 
the tumor being more than 10 cm, a suspicion of malignant 
disease, and the patient being clinically unstable.[26]
The definitive diagnosis of an OL requires a demonstration 
of the smooth muscle nature of the tumor by histology 
and immunohistochemistry.[11,12] On histology, OLs must be 
distinguished from cellular fibromas and stromal sclerosing 
tumors of the ovary.[13] The index case showed positivity 
with SMA and desmin, and was negative with Inhibin; 
immunohistochemical features were consistent with 
leiomyoma of the ovary. Ki-67, a marker of proliferative index, 
was low. OL must be differentiated from leiomyosarcoma 
using features such as mitotic activity, the presence of 
necrosis, and cytological atypia.[1,10]
The chosen approach for treatment of an ovarian mass 
should be individualized depending on factors such as the 
age of the patient, type and severity of clinical symptoms, 
risk of malignancy, desire for future fertility, and proximity to 
menopause.[29] Ovarian-preserving surgery should be offered 
to adolescent girls and reproductive age women, while 
hysterectomy with removal of the adnexa is appropriate for 
perimenopausal and postmenopausal women.[26] Preservation 
of ovarian function is even more of an important consideration 
in cases with bilateral disease, and oocyte cryopreservation 
may be considered in these cases.[20]
Accurate diagnosis of benign disease in the preoperative 
period is critical to ensuring that ovarian-preserving surgery 
can be offered to young patients.[7] van Esch et al. suggest 
that frozen sections be obtained for diagnosis from the 
ovarian mass during an initial elective diagnostic procedure 
to prevent the need for a second laparoscopic surgery or 
for laparotomy.[2] There are several considerations that help 
the surgeon to choose between laparoscopy and laparotomy 
including the size of the mass and the risk of malignancy.[2,26] 
Surgery may be offered by laparoscopic approach during 
pregnancy if the OL is symptomatic and/or associated with 
rapid growth.[4]
Conclusion
We have described the case of a medium-sized OL coexisting 
with uterine leiomyoma. OL may be under-reported 
from Africa. There was no associated pain in spite of the 
size (13 mm) and multiple adhesions from a previous 
myomectomy. The occurrence of abdominal pain appears to 
be proportional to the size of an ovarian mass and its ability 
to exert a mass effect on adjacent tissues. The determination 
of the size of an ovarian mass at ultrasonography is useful 
for predicting the occurrence of associated symptoms, 
complications, the risk of malignancy, and the success of 
laparoscopic surgery. The chosen approach for treatment of 
an ovarian mass should be individualized depending on the 
age of the patient, type and severity of clinical symptoms, 
risk of malignancy, desire for future fertility, and proximity 
to menopause.
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